Ticker News
$PPCB News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Propanc says preclinical PRP remodels chemo‑resistant pancreatic cells, supports Phase 1b in Q1 2027
Propanc (PPCB) released preclinical data showing its lead proenzyme formulation PRP reprograms chemotherapy‑resistant pancreatic cancer cells and that PRP pre‑treatment increased subsequent sensitivity to chemotherapy, results the company says support a planned First‑In‑Human Phase 1b study in Q1 2027. In vitro models reported PRP cut proliferation ~50% (54% in resistant cells), reduced clonogenic survival, migration and invasion, reversed EMT markers (E‑cadherin up, vimentin/snail down) and showed stronger effects when combined with a TGF‑β inhibitor, though responses varied by model and no in vivo or clinical efficacy data were presented.
PPCB: Published pilot study shows PRP cuts pancreatic tumor weight ~86% in mice and shows supportive patient survival signal
Propanc published a peer-reviewed pilot study reporting that its PRP proenzyme (trypsinogen:chymotrypsinogen A, 1:6) showed synergistic growth inhibition across 24 cancer cell lines and produced an 85.9% reduction in mean tumor weight in a syngeneic orthotopic pancreatic (Pan02) mouse model and ~50% inhibition in an orthotopic ovarian model, with evidence of anti-angiogenic, anti‑metastatic and EMT‑reversal activity. The paper also reports an observational UK Specials cohort (n=46) treated with a rectal proenzyme formulation where mean survival was 9.0 months versus an expected 5.6 months (p<0.05) and no severe treatment‑related adverse events were observed. These are pilot, preclinical and non‑randomized observational findings (and include different routes/formulations between animal IV dosing and the UK rectal use) that will need controlled clinical trials for confirmation.
PPCB: PRP shows >90% tumor growth inhibition and >2.5x survival in preclinical pancreatic cancer; Phase 1b planned Q1 2027
Propanc reported preclinical PRP data showing >90% mean tumor growth inhibition vs vehicle in orthotopic and patient-derived PDAC models (p<0.001), with marked reductions in liver/peritoneal metastases, tumor microenvironment remodeling (less fibrosis/EMT, lower CAF activity) and chemosensitization; median overall survival in animals increased >2.5-fold. The company says PRP (an IV trypsinogen+chymotrypsinogen combo, not a RAS inhibitor) holds FDA orphan status, is genotype-agnostic, and will enter a multicenter open-label Phase 1b first-in-human study in Q1 2027 (up to 50 advanced solid-tumor patients); Propanc positions PRP as a complementary approach to Revolution Medicines' recently FDA-approved daraxonrasib.
PPCB: PRP shows >90% tumor inhibition and >2.5x survival in preclinical PDAC; pitched as complement to ERAS-0015
Propanc (PPCB) issued a comparative analysis highlighting preclinical PRP results in advanced PDAC models showing >90% mean tumor-growth inhibition, marked metastasis/fibrosis reduction, and >2.5× median overall survival versus controls. The company positions PRP — an IV proenzyme combo that reverses EMT, depletes cancer stem cells and remodels the tumor microenvironment — as a genotype-agnostic, potentially complementary approach to RAS-targeting agents like Erasca’s ERAS-0015 (reported Phase 1 uORRs ~40–57% and FDA Fast Track); Propanc plans a Phase 1b first-in-human study (~40–50 pts) with first dosing targeted for Feb 2027.
Propanc (PPCB) pitches preclinical PRP EMT-reversal as complement to RAS inhibitors, plans Phase 1b Feb 2027
Propanc (PPCB) published a comparative analysis arguing its lead candidate PRP — an IV trypsinogen/chymotrypsinogen proenzyme combo that reverses EMT, depletes cancer stem cells and remodels the tumor microenvironment — could complement RAS inhibitors (Revolution’s daraxonrasib, Erasca’s ERAS-0015) by targeting residual mesenchymal/stem-like cells that drive resistance and metastasis. PRP efficacy cited is preclinical (orthotopic and PDX PDAC models: >90% tumor-growth inhibition, marked metastasis reduction, >2.5× median OS) and Propanc plans a multicenter open-label Phase 1b first-in-human study in Feb 2027 for up to 50 advanced solid-tumor patients; the company emphasized comparisons are directional and not head-to-head.
Leifras wins 3-year Nagoya City contract to operate school club instructor bank
Leifras (Nasdaq: LFS) was awarded a three-year renewal by Nagoya City to continue operating the "Nagoya Club Activities Human Resources Bank," recruiting, training and matching instructors for the city's new sports and cultural after-school programs at elementary schools starting Sept. 1, 2026. The company plans large-scale recruitment (targeting several hundred instructors/year), comprehensive safety- and instruction-focused training and a matching database, and says it will apply lessons from the project to build similar school-club infrastructure nationwide; financial terms were not disclosed.
PPCB preclinical PRP shows >90% tumor inhibition and >2.5x survival in pancreatic cancer models
Propanc (PPCB) reported preclinical orthotopic and patient-derived xenograft PDAC data where intravenous PRP (three times weekly) produced >90% mean tumor growth inhibition versus vehicle (p<0.001), markedly reduced liver and peritoneal metastases, remodeled the tumor microenvironment, enhanced sensitivity of chemo‑resistant cells to gemcitabine/nab‑paclitaxel, and extended median overall survival >2.5‑fold versus controls. These are animal xenograft results only; the company is advancing GMP manufacture, PK assay validation, holds FDA Orphan Drug designation for pancreatic cancer, and is preparing a Phase 1b First‑in‑Human study in ~40–45 patients with a clinical trial application expected in the coming months.
Propanc publishes peer‐reviewed study showing scalable production of recombinant rec‐PRP proenzymes
Propanc reported a peer‐reviewed publication showing scalable recombinant production of trypsinogen and chymotrypsinogen (rec‐PRP) in Komagataella phaffii with stable purified proteins using co‐expression of HAC1 and PDI1. The company plans small‐scale, non‐GMP production of rec‐PRP to test compatibility with its bovine‐derived lead PRP (which targets a Phase 1b first‐in‐human study in advanced solid tumors in early 2027) and highlights potential advantages like crystallized product stability for distribution without refrigeration.
PPCB signs MOU with Avance to run Phase 1b first‐in‐human PRP trial
Propanc (PPCB) signed a Memorandum of Understanding with Avance Clinical to support the clinical delivery of its Phase 1b first‐in‐human trial of PRP in patients with advanced solid tumors. The planned study will evaluate safety, tolerability, PK, immunogenicity and preliminary activity; Avance highlights early‐phase oncology experience, adaptive dose‐escalation designs and use of Australian regulatory/tax advantages to accelerate start‐up.
PPCB inks MOU with Avance to run Phase 1b First‐in‐Human trial of PRP
Propanc Biopharma (PPCB) signed a Memorandum of Understanding with Avance Clinical to support the clinical delivery of a First‐in‐Human Phase 1b trial of its lead candidate PRP in advanced solid tumors; the planned study will evaluate safety, tolerability, pharmacokinetics, immunogenicity and preliminary clinical activity. Avance positions itself as an experienced early‐phase oncology CRO that will leverage Australian advantages (faster ethics approval and an R&D tax rebate) to accelerate the program, but the announcement is an MOU of intent rather than a finalized services contract and provides no timelines, patient counts, or costs.
Propanc starts $5.0M buyback, begins with $500k tranche over 30 days
Propanc Biopharma (PPCB) initiated a $5.0 million share repurchase program and said it will repurchase an initial tranche of up to $500,000 over the next 30 days, using methods including open-market purchases, negotiated transactions, block trades and 10b5-1 plans. The company framed the buyback as reflecting value as its lead candidate PRP advances toward the clinic, but the program does not obligate any specific share purchases and may be modified, suspended or discontinued at any time.
Propanc tours European CDMO; sets Aug/Oct/Dec 2026 timetable for GMP PRP ahead of Phase 1b (30–40 pts)
Propanc's CEO visited a European CDMO and the company announced target dates to prepare PRP for its planned Phase 1b first-in-human trial: preproduction in Aug 2026, an engineering run in Oct 2026, and GMP manufacture starting Dec 2026, with four weeks of stability data expected to support an Australian clinical trial application in 2026. PRP is an IV weekly fixed combination of two proenzymes (trypsinogen and chymotrypsinogen); securing a CDMO partner and defining a near-term manufacturing timetable reduces a key operational hurdle ahead of dosing but execution risks and regulatory acceptance remain.
PPCB lines up CDMO GMP runs for PRP ahead of Phase 1b FIH in 30–40 patients
Propanc's CEO visited a European CDMO and the company set target dates to prepare PRP for a First‐In‐Human Phase 1b: preproduction August 2026, engineering run October 2026 and GMP manufacture starting December 2026, with four weeks of stability data expected to support an Australian clinical trial application in 2026. PRP is a fixed IV combination of two proenzymes (trypsinogen and chymotrypsinogen) planned for once‐weekly dosing in a 30–40 patient advanced solid tumor FIH study aiming to address cancer recurrence/metastasis.
ShareStructure.io launches free platform to flag dilution and financing risks (EDHL, PPCB, GLXG cited)
ShareStructure.io launched a free investor education and research platform focused on public company capital structures, SEC filings, financing transactions and dilution risks, offering a 10‐module course, watchlists and proprietary filing-analysis tools. The platform calls out example tickers — EDHL (7M selling shares vs ~541K float, ~12.9x overhang), PPCB (Series C preferred converting at 85% of low trading price backed by a $99M-face warrant, high dilution risk on ~464K float), and GLXG (variable-rate convertible notes registered) — to illustrate the kinds of financing-related issues users can track.
Propanc (PPCB) authorizes $5.0M share buyback
Propanc Biopharma (PPCB) approved a share repurchase program authorizing up to $5.0 million of its common stock to be bought opportunistically via open-market purchases, 10b5-1 plans, block trades or other methods. Management cites advancing its lead candidate PRP into a Phase 1b first‐in‐human study in 30–40 advanced cancer patients and an FDA orphan drug designation for pancreatic cancer as reasons the stock is undervalued.
PPCB CEO attends ageing/rejuvenation keynote, reiterates PRP Phase 1b timeline
Propanc Biopharma CEO James Nathanielsz attended a University of Granada keynote by leading regenerative researcher Dr. Juan Carlos Izpisúa and positioned the company's proenzyme-based research within the broader rejuvenation/regenerative medicine field. The company said it will continue collaborations with the Universities of Granada and Jaén on cell-rejuvenation work and reiterated that its lead asset PRP is on schedule to enter a Phase 1b First‐In‐Human study in advanced cancer patients.